Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Issue 4 (15th February 2017)

• Record Type: Journal Article
• Authors: Tan, Li; Gurbani, Deepak; Weisberg, Ellen L.; Jones, Douglas S.; Rao, Suman; Singer, William D.; Bernard, Faviola M.; Mowafy, Samar; Jenney, Annie; Du, Guangyan; Nonami, Atsushi; Griffin, James D.; Lauffenburger, Douglas A.; Westover, Kenneth D.; Sorger, Peter K.; Gray, Nathanael S.
• Is Part Of: Bioorganic & medicinal chemistry. Volume 25:Issue 4(2017)
• Page Start: 1320
• Page End: 1328
• Publication Date: 2017-02-15
• Subjects: TAK1 -- Polypharmacology -- Multitarget -- Cancer -- Cytokine secretion; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; Chemistry, Clinical -- Periodicals; Chemistry, Organic -- Periodicals; Chimie bio-organique -- Périodiques; Chimie pharmaceutique -- Périodiques; 615.19
• DOI: 10.1016/j.bmc.2016.11.034
• Languages: English
• ISSNs: 0968-0896

Abstract

Graphical abstract: Abstract: Targeted polypharmacology provides an efficient method of treating diseases such as cancer with complex, multigenic causes provided that compounds with advantageous activity profiles can be discovered. Novel covalent TAK1 inhibitors were validated in cellular contexts for their ability to inhibit the TAK1 kinase and for their polypharmacology. Several inhibitors phenocopied reported TAK1 inhibitor 5Z-7-oxozaenol with comparable efficacy and complementary kinase selectivity profiles. Compound5 exhibited the greatest potency in RAS-mutated and wild-type RAS cell lines from various cancer types. A biotinylated derivative of5, 27, was used to verify TAK1 binding in cells. The newly described inhibitors constitute useful tools for further development of multi-targeting TAK1-centered inhibitors for cancer and other diseases.